Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
Cancers · 18.06.2023 · 15 (12) · 3233
DOI: 10.3390/cancers15123233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.06.2023. Verfasst von Apostolos Papachristos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drugs’ safety and effectiveness are evaluated in randomized, dose-ranging trials in most therapeutic areas. However, this is only sometimes feasible in oncology, and dose-ranging studies are mainly limited to Phase 1 clinical trials. Moreover, although new treatment modalities (e.g., small molecule targeted therapies, biologics, and antibody-drug conjugates) present different characteristics compared to cytotoxic agents (e.g., target saturation limits, wider therapeutic index, fewer off-target side effects), in most cases, the design of Phase 1 studies and the dose selection is still based on the Maximum Tolerated Dose (MTD) approach used for the development of cytotoxic agents. Therefore, the dose was not optimized in some cases and was modified post-marketing (e.g., ceritinib, dasatinib, niraparib, ponatinib, cabazitaxel, and gemtuzumab-ozogamicin). The FDA recognized the drawbacks of this approach and, in 2021, launched Project Optimus, which provides the framework and guidance for dose optimization during the clinical development stages of anticancer agents. Since dose optimization is crucial in clinical development, especially of targeted therapies, it is necessary to identify the role of pharmacological tools such as pharmacogenomics, therapeutic drug monitoring, and pharmacodynamics, which could be integrated into all phases of drug development and support dose optimization, as well as the chances of positive clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
- Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA.
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 16121 Athens, Greece.
- Laboratory of Pharmacogenomics and Individualized Therapy, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece.
- Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
- Zayed Center for Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
ORCID-Profile: Apostolos Papachristos, Maria Vasileiou, George P Patrinos
Zitieren
APA
Papachristos, A., Patel, J., Vasileiou, M., & Patrinos, G. P. (2023). Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics. Cancers, 15(12), 3233. https://doi.org/10.3390/cancers15123233
Vancouver
Papachristos A, Patel J, Vasileiou M, Patrinos GP. Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics. Cancers. 2023;15(12):3233. doi:10.3390/cancers15123233
BibTeX
@article{Papachristos2023,
author = {Papachristos, Apostolos and Patel, Jai and Vasileiou, Maria and Patrinos, George P},
title = {Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics},
journal = {Cancers},
year = {2023},
volume = {15},
number = {12},
pages = {3233},
doi = {10.3390/cancers15123233}
}
EUVIMED